Abstract Number: 0080 • ACR Convergence 2026
Baseline cfDNA Active Chromatin Profiles Reflect Synovial Pathotype-Associated Biology Distinguishing Response to Targeted Treatments in Rheumatoid Arthritis
Background/Purpose: Synovial biopsy studies have identified genes and distinct patterns of histomorphology, hypothesized to represent "pathotypes" (including lymphoid-rich, myeloid-dominant, and pauci-immune/fibroid states) associated with differential…Abstract Number: 2286 • ACR Convergence 2026
Bimekizumab for the treatment of Psoriatic Arthritis (PsA): a cost-per-responder (CPR) analysis
Background/Purpose: Bimekizumab and risankizumab are approved for the treatment of PsA in multiple countries worldwide. The Phase 3b BE BOLD trial demonstrated superior efficacy of…Abstract Number: 0264 • ACR Convergence 2026
Distinct Multi-omic Signature Predicts Post-MMF Withdrawal Flares in Systemic Lupus Erythematosus Patients
Background/Purpose: Systemic lupus erythematosus (SLE) typically follows a relapsing-remitting course. Mycophenolate mofetil (MMF) is a cornerstone therapy for SLE, yet long‑term use is limited by…Abstract Number: 2291 • ACR Convergence 2026
Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Phase 3 Trials for PsA: Achievement of Minimal Disease Activity, Individual Components, and Very Low Disease Activity Through Week 52
Background/Purpose: Minimal disease activity (MDA) is a validated composite treatment target in PsA associated with improved long-term outcomes.1 Very low disease activity (VLDA) represents the…Abstract Number: 0277 • ACR Convergence 2026
Real-World Impact of Anifrolumab in Systemic Lupus Erythematosus: Insights from a Nationwide Spanish Multicenter Registry
Background/Purpose: Anifrolumab (ANI) is a human monoclonal antibody targeting type I interferon receptor subunit 1 (IFNAR1), approved for the treatment of adults with moderate-to-severe systemic…Abstract Number: 2292 • ACR Convergence 2026
Early Anti-TNF Therapy Added to Methotrexate versus Methotrexate Alone in Psoriatic Arthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Psoriatic arthritis is a chronic inflammatory disease in which early control of disease activity improves clinical outcomes, and methotrexate remains the most commonly used…Abstract Number: 0305 • ACR Convergence 2026
Deep Renal Response at 24 months in Lupus Nephritis
Background/Purpose: Deep renal response (DR), defined as urine protein-to-creatinine ratio (UPCR) ≤150 mg/g with stable renal function, has been proposed as a stringent treatment target…Abstract Number: 0357 • ACR Convergence 2026
Defining Meaningful Change in ASAS-HI in Patients With Axial Spondyloarthritis: Associations With Core Outcomes and Discrimination of Thresholds of Change in Late Phase Clinical Trials of Upadacitinib
Background/Purpose: Assessment of SpondyloArthritis international Society Health Index (ASAS-HI) is a patient-reported linear composite measure validated for global functioning and health in axial spondyloarthritis (axSpA),1…Abstract Number: 0383 • ACR Convergence 2026
Clinical Characteristics of Difficult-to-Manage Psoriatic Arthritis: A Single-Center Comparative Cohort Study
Background/Purpose: Despite advances in targeted therapy, a substantial subset of patients with psoriatic arthritis (PsA) fail to achieve sustained disease control 1,2. EULAR defines difficult-to-manage…Abstract Number: 0726 • ACR Convergence 2026
Temporal Treatment-Response Patterns Across Rheumatoid Arthritis Core Set Domains: A Patient-Level Analysis of Randomized Trials
Background/Purpose: The composite American College of Rheumatology (ACR) 20%, 50% and 70% response endpoints are widely used in rheumatoid arthritis (RA) clinical trials. We have…Abstract Number: 1031 • ACR Convergence 2026
Four-week Changes in Collagen Degradation Biomarkers are Prognostic of 24-week Clinical Response in Psoriatic Arthritis: A Biomarker-Guided Stratification Approach
Background/Purpose: To determine whether early changes in extracellular matrix (ECM) remodelling biomarkers identify biologically distinct subgroups of patients with psoriatic arthritis (PsA) and whether such…Abstract Number: 1039 • ACR Convergence 2026
Baseline Epiproteomics Reveals Proteoform-Level Separation Between TNF Inhibitor Responders and Non-Responders in Rheumatoid Arthritis
Background/Purpose: Post-translational modifications (PTMs) regulate protein structure, function, and interactions. In rheumatoid arthritis (RA), citrullination is a defining molecular feature, motivating broader interrogation of PTM-driven…Abstract Number: 1244 • ACR Convergence 2026
TRM-SLE disease activity thresholds capture the majority of patients in a Phase 2 clinical trial dataset
Background/Purpose: The efficiency of clinical trials in SLE can potentially be improved with the use of clinical outcome assessments (COAs) that are designed specifically to…Abstract Number: 1294 • ACR Convergence 2026
Three-Month Renal Response Markers Associated With Failure to Achieve Complete Renal Response Within 6-12 Months in a Multidisciplinary Lupus Nephritis Clinic
Background/Purpose: The 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis (LN) emphasizes serial proteinuria monitoring and complete…Abstract Number: 1324 • ACR Convergence 2026
Predictors of b/tsDMARD Discontinuation and Treatment Response in Psoriatic Arthritis: Results from the British Society for Rheumatology Psoriatic Arthritis Register
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous, multi-domain disease, and real-world treatment outcomes of biologic and targeted synthetic DMARDs often differ from those observed in…
ACR Meeting Abstracts